News >

Low NR2F1 Expression May Predict Risk of Metastatic Breast Cancer

Caroline Seymour
Published: Tuesday, Nov 06, 2018

Julio Aguirre-Ghiso, PhD

Julio Aguirre-Ghiso, PhD

Low NR2F1 expression in disseminated tumor cells (DTCs) that is found in bone marrow may be indicative of developing metastatic breast cancer, according to results of a study published in Breast Cancer Research.

"Improved techniques to assess the population of patients with residual disease and their dormant or reactivating state will be key to identifying the risk of future metastasis despite undergoing standard treatment,” said Aguirre-Ghiso. “This opens the way for testing new treatments that prevent metastasis by inducing dormancy or eradicating the dormant disseminated cancer cells that have not yet initiated metastatic growth."
Borgen E, Rypdal M, Soledad Sosa M, et. al. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients [published online October 16, 2018]. Breast Cancer Res. doi: 10.1186/s13058-018-1049-0.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast CancerDec 31, 20191.0
Medical Crossfire®: A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer ForwardJan 31, 20201.0
Publication Bottom Border
Border Publication